Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP Phenotyping for Sunitinib and Erlotinib Dosing
NCT01402089Phase 4Completed
- Start
- Jan 2012
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sunitinib and erlotinib in renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and non-small cell lung cancer (NSCLC) (2 cohorts). Primary endpoint: Steady-state partial area-under the plasma concentration-time curve over 24 hours at 2 weeks. Started Jan 2012; status: completed.
02
Drugs
sunitiniberlotinib
03
Conditions
renal cell carcinoma (RCC)gastrointestinal stromal tumor (GIST)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01402089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01402089.